What Maxigesic is Used For: Main Therapeutic Areas

Maxigesic, a fixed-dose combination of paracetamol and ibuprofen, is applied across domains where additional symptomatic support is needed, relevant in contexts marked by increased discomfort or tension.

This formulation is indicated for the temporary relief of pain and fever. The combination is commonly used to help manage symptoms related to physical discomfort and symptoms related to inflammatory or irritative states. This approach contributes to easing the overall symptom load during periods of heightened symptoms.

The medicine may assist with managing symptoms that become more disruptive during flare-ups, such as discomfort involving the head, mouth, and muscles, or during menstruation, and discomfort associated with colds and flu.

In contexts involving heightened systemic burden, the supportive effect of the combination contributes to improved comfort during periods of heightened symptoms.

“The use of this combination is applied in addressing symptom clusters that may become temporarily overwhelming, providing support that helps ease the overall symptom burden.”

---

Quick Fact: Relevant when supportive symptom management is appropriate.

---

Regulatory References

1. Maxigesic is indicated for the temporary relief of pain and fever

Official Population Eligibility and Restrictions

This medicine is approved for use in Adults and Adolescents aged 12 years and over. Use is not recommended in children under 12 years because the safety and efficacy have not been established by regulatory authorities.

Populations Who Must Not Use the Medicine (Contraindications)

Use is contraindicated (absolutely prohibited) for patients with specific health conditions, including:

• Known hypersensitivity to paracetamol, ibuprofen, aspirin, or any other Nonsteroidal Anti-inflammatory Drug (NSAID).
• Severe organ failure (severe heart failure classified as NYHA Class IV, severe renal failure, or severe hepatic failure).
• Active gastrointestinal disease, such as active peptic ulceration or active GI bleeding.
• During the third trimester of pregnancy.
• For managing peri-operative pain following Coronary Artery Bypass Graft (CABG) surgery [FDA Prescribing Information].

Conditional Use and Special Caution

Caution is required for geriatric patients (65 and over) due to an increased risk of adverse effects. The medicine should be used with caution in patients with a history of GI bleeding, uncontrolled hypertension, or non-severe impairment of renal, cardiac, or hepatic function [HPRA SmPC, NZ Regulatory Data Sheet]. Use is also restricted for women who are trying to conceive or who are breastfeeding.

Interactions with other medicines and products

Official regulatory documentation requires caution and places specific restrictions on the co-administration of Maxigesic (Acetaminophen and Ibuprofen) with certain medicinal and non-medicinal substances.

Regulatory Contraindicated Combinations

Co-administration with the following medicine classes is explicitly forbidden due to the potential for augmented toxicity and adverse event risk:

• Other Acetaminophen-containing Products: Prohibited due to the dose-dependent risk of severe liver damage (hepatotoxicity).
• Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Prohibited, including aspirin at analgesic doses, due to a documented increase in the risk of serious gastrointestinal adverse events, such as bleeding and ulceration.

Documented Pharmacodynamic and Pharmacokinetic Interactions

Interactions defined in official labels often result in altered efficacy of co-administered agents or modification of their concentrations:

• Antihypertensive Medicines and Diuretics: The Ibuprofen component can impair the efficacy of antihypertensive medicines (e.g., ACE inhibitors, ARBs) and reduce the natriuretic effect of diuretics, requiring monitoring during co-use.
• Drugs that Interfere with Hemostasis: Co-administration with agents like Warfarin or SSRIs increases the documented risk of bleeding.
• Digoxin: Use may result in an increase in the serum concentration and a prolongation of the half-life of Digoxin.

Population and Substance-Specific Constraints

Regulatory information specifies certain constraints related to specific populations and common substances:

• Alcohol: Severe liver damage is documented to occur if three or more alcoholic drinks are consumed every day while using the product.
• Advanced Age: Caution is required in patients aged 65 and older due to a documented increased risk of adverse effects, including heart failure and renal impairment, associated with the Ibuprofen component.

Maxigesic exerts its action through a coordinated dual-pathway approach, combining the pharmacodynamic effects of Acetaminophen and Ibuprofen to modulate physiological responses related to nociceptive signaling and central thermoregulatory processes. This strategy targets specific enzyme systems and signaling processes in both the central and peripheral nervous systems.

Dual Inhibition of Prostaglandin Synthesis

This core domain addresses the drug's action on Cyclooxygenase (COX) enzymes. Ibuprofen non-selectively inhibits COX-1 and COX-2 in both peripheral tissues and the CNS, while Acetaminophen exerts a functional inhibitory effect primarily within the CNS. This inhibition limits the production of prostaglandins ( PGE2), chemical mediators responsible for sensitizing nerve endings and elevating the body's thermoregulatory set point, which results in the reduction of heightened signaling.

Central Nociceptive and Thermoregulatory Modulation

Acetaminophen acts centrally, not only via COX inhibition in the hypothalamus but also through the action of its metabolite ( AM404) on the TRPV1 receptor and the endocannabinoid system. This modulation engages descending neural pathways to increase the threshold for nociceptive signal processing, which modulates activity within targeted neural circuits.

Mechanistic Synergy (Peripheral-Central Partnership)

The combination engages a synergistic partnership where Ibuprofen's peripheral anti-inflammatory mechanism compensates for the limited anti-inflammatory efficacy of Acetaminophen in high-peroxide environments. This combined strategy ensures simultaneous modulation of both the peripheral signaling input and the central interpretation of those signals, resulting in the concurrent modulation of these physiological pathways.

How to Use Maxigesic: Administration Guidelines

This section outlines the label-based instructions for the fixed-dose combination of paracetamol and ibuprofen (Maxigesic/Combogesic), detailing the approved routes, dosing limits, and administration specifics.

---

Approved Forms and Routes of Administration

Maxigesic is available in two primary forms, each with a designated route of administration:

• Oral Tablet: Used for oral administration, typically containing 500 mg paracetamol and 150 mg ibuprofen per tablet.
• Solution for Infusion (IV): Used for intravenous administration in hospital settings, often containing 1000 mg paracetamol and 300 mg ibuprofen.

---

Standard Dosing and Frequency

Feature	Oral Tablet Instructions (Adults/12 years and older)	IV Infusion Instructions (50 kg and over)
Single Dose	1 to 2 tablets	1000 mg Paracetamol / 300 mg Ibuprofen
Dosing Frequency	Every six hours (q6h), as required	Every six hours (q6h), as required
Maximum Daily Limit	Eight tablets in 24 hours	4000 mg Paracetamol / 1200 mg Ibuprofen

Note on Paracetamol Limit: The total daily dose of paracetamol from all sources must not exceed 4000 mg (4 g).

---

Administration Requirements and Duration

• Oral Intake: The tablet should be taken with a full glass of water.
• IV Administration: The solution is required to be administered as a slow infusion over 15 minutes.
• Duration of Use: The product is strictly designated for short-term use only. The oral tablets are generally limited to a few days at a time, and the IV infusion is typically limited to five days or less.

Research Evidence / Overview of Studies for Maxigesic

The fixed-dose combination of acetaminophen and ibuprofen was studied for use in managing acute symptom patterns. This section summarizes the structure and scope of the clinical research. The goal of this research was to evaluate the fixed-dose combination against its individual ingredients or a placebo in defined study settings.

Research examined the medicine's use in settings marked by acute or disruptive episodes.

Evidence for Use in Acute Post-Surgical Pain

Research exploring how symptoms change over time has focused heavily on the medicine’s use in managing pain experienced immediately after surgery.

Studies in the Acute Oral/Dental Surgery Setting

Studies conducted during periods of increased symptom activity have often utilized short-term Randomized Controlled Trials (RCTs) that were double-blind and placebo-controlled. Research examined specific patient-reported outcomes describing perceived discomfort following standardized procedures, such as third molar (wisdom tooth) extractions.

Studies monitored measurements of pain intensity difference scores over a 24- to 48-hour period. The evidence in this specific acute pain model is generally classified as High.

However, there is limited information for long-term outcomes because follow-up durations were limited, typically focusing only on the immediate 48-hour post-operative period. Data for long-term effects are not fully established.

Studies in Major Orthopedic and General Surgery

Studies explored the medicine’s use following more extensive procedures, such as orthopedic and general surgery. These trials primarily monitored outcomes reflecting daily functioning or activity level and the consumption of supplementary pain relievers (opioids) during the recovery period.

Findings describe patterns observed in the studies, including the measurement of opioid consumption compared to control groups. The results apply only to the populations studied and generally cover the acute, in-hospital phase (up to five days). There is limited information for long-term outcomes.

Evidence for Use in Elevated Body Temperature (Fever)

The medicine was studied for use in temporary physiological imbalance related to fever. Research primarily involved highly controlled Randomized Controlled Trials (RCTs) using models designed to induce elevated body temperature in healthy volunteers.

Studies monitored the rate and magnitude of temperature change following administration. This evidence is generally classified as Moderate. The specific, controlled model used in some research does not replicate the full complexity and diversity of fever caused by various clinical infections. Consequently, few data are available from prospective trials that observe the fixed-dose combination's use in a general practice setting.

Research for Acute Non-Surgical Pain Symptoms

The combination was studied for use in acute conditions where symptoms may vary in intensity, such as headache or general musculoskeletal discomfort. Research included short-term trials and Systematic Reviews.

However, findings were mixed in certain non-surgical pain models, particularly when monitored alongside the single-agent components. Evidence quality varies across studies, leading to a classification of Moderate/Inconsistent across the breadth of non-surgical pain research. Comparative evidence is lacking for many specific non-surgical pain contexts.

Key Limitations and Research Gaps

Limitations include:

• Follow-up durations were limited across most efficacy trials, restricting understanding of effects beyond the acute phase.
• Data for certain groups remain insufficient, including evidence for long-term outcomes, and specific information for pediatric and older adult populations.
• Findings were mixed in some non-surgical acute pain contexts, indicating that the findings were mixed in some trials when monitored alongside monotherapy across all pain types.
• The results apply only to the specific conditions and patient groups under which they were conducted, and research does not determine whether an individual will respond similarly.

Key Studies & References

1. MAXIGESIC® (PARACETAMOL / IBUPROFEN) TABLETS: Australian Therapeutic Goods Administration Product Information

Common questions about Maxigesic (FAQ)

---

Q: Why would someone choose Maxigesic instead of separate tablets?

Studies and official documents describe the fixed-dose combination as offering higher pain relief scores and a superior analgesic effect in specific acute pain models compared to taking paracetamol (acetaminophen) or ibuprofen alone. The combination approach is designed to utilize both active substances concurrently for comprehensive symptom relief.

---

Q: How quickly is Maxigesic expected to start working?

Research supporting the product's approval has indicated a faster onset of action compared to the individual ingredients when administered separately. This finding is based on studies supporting the regulatory approval of the product.

---

Q: What is the usual duration of the pain relief from Maxigesic?

The approved dosing frequency described in regulatory documents is typically every six hours (q6h). This standard administration interval is the intended duration of pain relief before the next dose is considered.

---

Q: Is Maxigesic generally taken for short-term pain relief?

Official regulatory labels strictly designate the product for short-term use only. For the oral tablet form, this duration is generally limited to a few days at a time for adults, as documented in the administration requirements.

---

Q: Can Maxigesic be taken with or without food?

The official administration instructions specify that the tablet should be taken with a full glass of water. Regulatory information does not provide specific directions regarding taking the medicine with food.

---

Q: Are there different strengths or formulations of Maxigesic available?

Regulatory records confirm the existence of multiple registered formulations. These include the standard oral tablet, a solution for intravenous infusion (IV) for hospital use, and, in some regions, an oral liquid for other patient groups.

---

Q: Does Maxigesic have the potential to cause stomach irritation?

Official safety documents list gastrointestinal disturbances as common adverse reactions. These effects may include nausea, dyspepsia (indigestion), and abdominal pain.

---

Q: Can Maxigesic be used for treating muscle pain?

The approved indications described in the official product information include the temporary relief of muscular pain. It is also indicated for rheumatic pain.

---

Q: Is Maxigesic generally suitable for people with asthma?

Official product warnings state that the medicine should be avoided by people with asthma unless specifically advised by a healthcare professional. This precaution is due to risks associated with the ibuprofen component.

---

Q: Does Maxigesic cause drowsiness or affect the ability to drive?

Regulatory documents note that side effects such as dizziness or somnolence (drowsiness) may occur. Patients are therefore cautioned to be careful driving or operating machinery until they are aware of how the medicine affects them.

---

Q: Does Maxigesic contain any addictive substances?

The Consumer Medicine Information (CMI) provided in some regions explicitly states that Maxigesic is not addictive. It is classified as a non-opioid analgesic combination.

---

Q: Are there specific age restrictions for using Maxigesic?

Official documents define a minimum approved age, contraindicating use in children under 12 years. Caution is also required for geriatric patients aged 65 years and over due to a documented increased risk of adverse effects in this age group.

---

Q: Is Maxigesic safe to use for fever reduction?

The approved indications for the product, as listed in the official documents, include the reduction of fever. Research has also specifically studied the medicine’s use for temporary elevated body temperature.

---

Q: Why are people with stomach ulcers sometimes advised not to use Maxigesic?

Official product information states that the medicine is contraindicated (prohibited) for those with active gastrointestinal disease, such as a peptic ulcer. This is due to a documented increased risk of gastrointestinal bleeding and ulceration from the ibuprofen component.

---

Q: Can Maxigesic affect fertility?

Regulatory information advises that the medicine may impair female fertility and is therefore not recommended for women who are trying to conceive. This specific effect is described as being reversible upon stopping the medicine.

---

Q: Is there a known effect of Maxigesic on sleep patterns?

The official regulatory documents list both somnolence (drowsiness) and insomnia as reported side effects. This indicates that the medicine has the potential to affect sleep patterns.

---

Q: What is the shelf life of Maxigesic tablets?

Official storage documents specify a labeled shelf-life of 3 years for the tablets. This duration is valid when the product is stored according to the recommended conditions, which typically require storage below 30degree C and protection from light.

---

Q: Are there any known long-term side effects associated with Maxigesic use?

Regulatory safety information notes that the risk of serious adverse events is associated with the NSAID component, particularly when used in high doses and for long-term treatment. These risks include the potential for Cardiovascular thrombotic events.

---

Q: Does Maxigesic interact with commonly used herbal supplements?

Regulatory documents issue a general caution against using the medicine with other products, including those bought without a prescription, such as herbalist products or herbal supplements. This is due to the potential for interactions.

---

Q: Can Maxigesic be used for dental pain?

The approved indications for the oral tablet formulation include the temporary relief of toothache. It is also specifically used to manage pain associated with dental procedures, as supported by clinical research.

---

Q: Is Maxigesic available in a liquid or suspension form?

Regulatory records confirm that an oral liquid (suspension) formulation for use in children has received approval in certain international jurisdictions. This is an alternative to the tablet form and the IV solution.

---

Q: Is the combination in Maxigesic more effective than using the ingredients separately?

Research supporting the regulatory approval of this product demonstrated that the combination offered higher pain relief scores and a superior analgesic effect in the studied acute pain models compared to taking equivalent doses of paracetamol or ibuprofen alone.

---

Q: What makes Maxigesic different from a single-ingredient NSAID (like ibuprofen alone)?

The product is designed to provide a dual-pathway approach to pain relief. It combines the central pain relief of paracetamol with the peripheral anti-inflammatory action of ibuprofen, which distinguishes its mechanism from a single-agent NSAID.

---

Q: Is the term 'enhanced' used to describe the combination in Maxigesic?

The general purpose of the formulation is described by official documentation as providing enhanced efficacy for general pain relief. The product is also widely referred to as having a 'dual-action' profile.

---

Q: What is the recommended period of time Maxigesic should be used for?

The product is strictly designated for short-term use only, according to the official administration instructions. For the oral tablet form, the duration is generally limited to a few days at a time for adults.

How to Store and Dispose of Maxigesic

Maxigesic tablets must be stored according to official regulatory requirements to ensure product stability and safety.

Storage Conditions and Requirements

• Temperature: Store the tablets below 30°C.
• Environmental Protection: Keep the medicine in a cool dry place and protect from light. Avoid storing in areas of high heat or dampness, such as the bathroom, near a sink, or on a window sill.
• Packaging: Keep the product in its original pack until the time of use.
• Child Safety: All medicine must be kept out of the sight and reach of children.

Disposal Instructions

Maxigesic has a labeled shelf-life of 3 years under the stated storage conditions. If the product is expired, damaged, or unused, it must be returned to a pharmacist for proper disposal. No special environmental waste requirements are noted beyond returning the product to a regulated collector.